XORTX THERAPEUTICS INC
XRTXNASDAQUS Equity
$2.12▲ $0.00 (+0.00%)
Live1h—
24h▲ 0.0%
7d▲ 0.0%
14d▲ 1.0%
30d▲ 3.9%
1y▼ 48.3%
🏦Market Cap
$4M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
21.0%
Moderate
💵FCF Margin
0.1%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
55
Weak
Trading Snapshot
- Day Range
- $2.11 – $2.13
- 52-Week Range
- $2.42 – $9.85
- Volume
- $3.75B
- Avg Volume
- $2.55B
- Shares Outstanding
- 1.8M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $528,548
- Last Q Revenue
- $134,280
- P/E Ratio
- —
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.65
- Dividend Yield
- —
Why Investors Own XRTX
- ✓High-growth profile — revenue up +51.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 79% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$528,548▲ +44.4% YoY
Gross Margin (TTM)
78.5%▲ +0.7% YoY
Operating Income (TTM)
$134,780▲ +44.4% YoY
Free Cash Flow (TTM)
$79,811▲ +44.4% YoY
About XORTX THERAPEUTICS INC
A company profile for XORTX THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
55/100
Analyst Ratings
ⓘConsensus
Buy
5 analysts
Strong Buy1
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Mar 2024
Latest News & Updates
🚀
Barron’s·2h ago
XORTX THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift XRTX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
XORTX THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.